跳至主要内容
临床试验/IRCT20190305042939N2
IRCT20190305042939N2招募中3 期

Evaluation of the effects of curcumin supplementation on oxidative stress indices in patients treated with cisplatin: a double-blind, placebo-controlled randomized clinical trial

Esfahan University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients with malignancy who receive cisplatin for the first time in their treatment regimens
  • GFR higher than 60 mL/min based on CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
  • The patient be able to receive curcumin orally

排除标准

  • Patients with active infection or symptoms of sepsis
  • Patients who have received nephrotoxic drugs such as aminoglycoside, amphotericin, vancomycin, colistin, media contrast, calcineurin inhibitors or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the past 72 hours
  • Patients who have a history of taking cisplatin
  • Patients who may experience complications or allergic reactions to curcumin during treatment
  • Patients who had a history of acute kidney injury ( AKI ) before entering the study
  • The patient's unwillingness to cooperate during the research
  • Patients with bilirubin above 2 mg / dl or liver enzymes above 2.5 times the normal level

研究者

相似试验